Compounding still constitutes unapproved new drug manufacturing under the FD&C Act, the floor that applies to all non-monograph peptides
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
Green recommends avoiding washing the treatment area for 24 hours after AquaGold to allow the microinfusions to absorb, and skipping oil-based makeup during that window
Improperly stored BPC-157 can degrade losing bioactivity, changing purity, and producing inconsistent research results
If it is important for you to understand whether this protocol is suitable in your specific case and you would like to receive individualized recommendations, you can book a consultation with us
PMC 6632124
-1.jpg)
